GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (NAS:PDSB) » Definitions » Shiller PE Ratio

PDS Biotechnology (PDS Biotechnology) Shiller PE Ratio : (As of May. 23, 2024)


View and export this data going back to 2015. Start your Free Trial

What is PDS Biotechnology Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


PDS Biotechnology Shiller PE Ratio Historical Data

The historical data trend for PDS Biotechnology's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDS Biotechnology Shiller PE Ratio Chart

PDS Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PDS Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PDS Biotechnology's Shiller PE Ratio

For the Biotechnology subindustry, PDS Biotechnology's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PDS Biotechnology's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDS Biotechnology's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where PDS Biotechnology's Shiller PE Ratio falls into.



PDS Biotechnology Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

PDS Biotechnology's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, PDS Biotechnology's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.3/131.7762*131.7762
=-0.300

Current CPI (Mar. 2024) = 131.7762.

PDS Biotechnology Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.000 100.560 0.000
201409 -5.140 100.428 -6.744
201412 -4.848 99.070 -6.449
201503 -6.820 99.621 -9.021
201506 -5.623 100.684 -7.359
201509 -9.252 100.392 -12.144
201512 -6.000 99.792 -7.923
201603 -6.400 100.470 -8.394
201606 -6.600 101.688 -8.553
201609 -7.400 101.861 -9.573
201612 -6.600 101.863 -8.538
201703 -8.400 102.862 -10.761
201706 -8.800 103.349 -11.221
201709 -7.400 104.136 -9.364
201712 -9.000 104.011 -11.402
201803 -0.240 105.290 -0.300
201806 -0.170 106.317 -0.211
201809 -0.210 106.507 -0.260
201812 -24.707 105.998 -30.716
201903 1.470 107.251 1.806
201906 -0.750 108.070 -0.915
201909 -1.100 108.329 -1.338
201912 -0.840 108.420 -1.021
202003 -0.390 108.902 -0.472
202006 -0.190 108.767 -0.230
202009 -0.210 109.815 -0.252
202012 -0.160 109.897 -0.192
202103 -0.140 111.754 -0.165
202106 -0.030 114.631 -0.034
202109 -0.240 115.734 -0.273
202112 -0.230 117.630 -0.258
202203 -0.320 121.301 -0.348
202206 -0.200 125.017 -0.211
202209 -0.260 125.227 -0.274
202212 -0.670 125.222 -0.705
202303 -0.320 127.348 -0.331
202306 -0.370 128.729 -0.379
202309 -0.350 129.860 -0.355
202312 -0.350 129.419 -0.356
202403 -0.300 131.776 -0.300

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


PDS Biotechnology  (NAS:PDSB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


PDS Biotechnology Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of PDS Biotechnology's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PDS Biotechnology (PDS Biotechnology) Business Description

Traded in Other Exchanges
Address
25B Vreeland Road, Suite 300, Florham Park, NJ, USA, 07932
PDS Biotechnology Corp operates as a clinical-stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Executives
Spencer D. Brown officer: Senior VP, General Counsel 25B VREELAND ROAD, SUITE 300, FLORHAM PARK NJ 07932
Matthew C Hill officer: Chief Financial Officer C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Delyle W Bloomquist director, 10 percent owner RAYONIER ADVANCED MATERIALS INC., 1301 RIVERPLACE BLVD., SUITE 2300, JACKSONVILLE FL 32207
Voorhees Seth Van officer: Chief Financial Officer 12 HARVEY DRIVE, SHORT HILLS NJ 07078
Kamil Ali-jackson director C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Gregory Gene Freitag director 13631 PROGRESS BLVD., ALACHUA FL 32615
Stephen C. Glover director 108 DOCKSIDE CIRCLE, WESTON FL 33327
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Michael N. King officer: Interim Chief Financial Office 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Ilian Iliev director 303 A COLLEGE ROAD EAST, PRINCETON NJ 08540
Janetta Trochimiuk officer: Principal Accounting Officer 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Richard Sykes director C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, FLORHAM PARK NJ 07932
Frank Bedu-addo director, 10 percent owner, officer: President/CEO 300 CONNELL DRIVE, SUITE 400, BERKELEY HEIGHTS NJ 07922
Lauren Wood officer: Chief Medical Officer 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922
Gregory Conn officer: Chief Scientific Officer 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922

PDS Biotechnology (PDS Biotechnology) Headlines

From GuruFocus